Literature DB >> 19143762

Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.

L Maggiorella1, C Aubel, C Haton, F Milliat, E Connault, P Opolon, E Deutsch, J Bourhis.   

Abstract

Angiogenesis is considered as an essential process for tumour development and invasion. Previously, we demonstrated that cyclin-dependent kinase inhibition by roscovitine induces a radiosensitization and a synergistic antitumoral effect in human carcinoma but its effect on the microenvironment and tumour angiogenesis remains unknown. Here, we investigated the effect of the combination roscovitine and ionizing radiation (IR) on normal cells in vitro and on tumour angiogenesis in MDA-MB 231 tumour xenografts. We observed that the combination roscovitine and IR induced a marked reduction of angiogenic hot spot and microvascular density in comparison with IR or roscovitine treatments alone. The Ang-2/Tie-2 ratio was increased in presence of reduced vascular endothelial growth factor level suggesting vessel destabilization. In vitro, no radiosensitization effect of roscovitine was found in endothelial, fibroblast, and keratinocyte cells. IR potentiated the antiproliferative effect of roscovitine without inducing apoptosis in endothelial cells. Roscovitine decreased IR-stimulated vascular endothelial growth factor secretion of MDA-MB 231 and endothelial cells. A reduction in the endothelial cells invasion and the capillary-like tube formation in Matrigel were observed following the combination roscovitine and IR. This combined treatment targets angiogenesis resulting in microvessel destabilization without inducing normal cell toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19143762      PMCID: PMC6496250          DOI: 10.1111/j.1365-2184.2008.00570.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  28 in total

Review 1.  MAP kinases and hypoxia in the control of VEGF expression.

Authors:  E Berra; G Pagès; J Pouysségur
Journal:  Cancer Metastasis Rev       Date:  2000       Impact factor: 9.264

2.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

Authors:  J A Foekens; H A Peters; N Grebenchtchikov; M P Look; M E Meijer-van Gelder; A Geurts-Moespot; T H van der Kwast; C G Sweep; J G Klijn
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

3.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Authors:  Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

4.  Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

Authors:  D H Gorski; M A Beckett; N T Jaskowiak; D P Calvin; H J Mauceri; R M Salloum; S Seetharam; A Koons; D M Hari; D W Kufe; R R Weichselbaum
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

5.  The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.

Authors:  B K Linderholm; T Lindahl; L Holmberg; S Klaar; J Lennerstrand; R Henriksson; J Bergh
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

Review 7.  Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.

Authors:  George W Sledge
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

8.  Combined effects of angiostatin and ionizing radiation in antitumour therapy.

Authors:  H J Mauceri; N N Hanna; M A Beckett; D H Gorski; M J Staba; K A Stellato; K Bigelow; R Heimann; S Gately; M Dhanabal; G A Soff; V P Sukhatme; D W Kufe; R R Weichselbaum
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

9.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

10.  Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.

Authors:  Laurence Maggiorella; Eric Deutsch; Valérie Frascogna; Nicole Chavaudra; Laurence Jeanson; Fabien Milliat; François Eschwege; Jean Bourhis
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

View more
  8 in total

1.  Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Seval Korkmaz; Esin Aktas; Cem Ovalioglu; Tolga Dundar; Hakan Seyithanoglu
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

2.  Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis.

Authors:  Johanna Liebl; Sabine B Weitensteiner; György Vereb; Lili Takács; Robert Fürst; Angelika M Vollmar; Stefan Zahler
Journal:  J Biol Chem       Date:  2010-09-07       Impact factor: 5.157

3.  Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.

Authors:  Nina Berberich; Bernd Uhl; Jos Joore; Ulrike K Schmerwitz; Bettina A Mayer; Christoph A Reichel; Fritz Krombach; Stefan Zahler; Angelika M Vollmar; Robert Fürst
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study.

Authors:  Oliver Riesterer; Christoph Oehler-Jänne; Wolfram Jochum; Angela Broggini-Tenzer; Van Vuong; Martin Pruschy
Journal:  Radiat Oncol       Date:  2011-06-08       Impact factor: 3.481

5.  Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.

Authors:  Binoj C Nair; Sreeram Vallabhaneni; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res       Date:  2011-08-11       Impact factor: 6.466

6.  RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.

Authors:  Andrea M Pesch; Nicole H Hirsh; Anna R Michmerhuizen; Kassidy M Jungles; Kari Wilder-Romans; Benjamin C Chandler; Meilan Liu; Lynn M Lerner; Charles A Nino; Connor Ward; Erin F Cobain; Theodore S Lawrence; Lori J Pierce; James M Rae; Corey W Speers
Journal:  JCI Insight       Date:  2022-02-08

7.  Screening and identification of small molecule inhibitors of ErbB2-induced invasion.

Authors:  D M Brix; B Rafn; K Bundgaard Clemmensen; S H Andersen; N Ambartsumian; M Jäättelä; T Kallunki
Journal:  Mol Oncol       Date:  2014-07-12       Impact factor: 6.603

8.  Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.

Authors:  Chung-Sheng Shi; Kuan-Lin Kuo; Mei-Sin Chen; Po-Ming Chow; Shing-Hwa Liu; Yu-Wei Chang; Wei-Chou Lin; Shih-Ming Liao; Chen-Hsun Hsu; Fu-Shun Hsu; Hong-Chiang Chang; Kuo-How Huang
Journal:  Cells       Date:  2019-11-19       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.